SEC Form 4 · accession 0001209191-17-030062
GENOMIC HEALTH INC · GHDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kimberly J Popovits
Officer — President and CEO · Director
Period of report
May 3, 2017
Accepted (ET)
May 4, 2017 · 5:12 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001131324
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 3, 2017 | M | 2,707 | $17.33 | A | 80,943 | D | |
| Common StockF1 | May 3, 2017 | M | 2,293 | $17.33 | A | 83,236 | D | |
| Common StockF2,F3,F4,F1 | May 3, 2017 | S | 2,707 | $31.6107 | D | 80,529 | D | |
| Common StockF2,F4,F5,F1 | May 3, 2017 | S | 2,293 | $31.9575 | D | 78,236 | D | |
| Common Stock | holding | — | — | — | 12,298 | I | Held by Morgan Stanley as Custodian for Benefit of Kimberly Popovits | |
| Common Stock | holding | — | — | — | 16,825 | I | Held in trust for the benefit of Ms. Popovits' son, of which Ms. Popovits is trustee. | |
| Common Stock | holding | — | — | — | 199,487 | I | Held by the Popovits 2010 Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F6 | $17.33 | May 3, 2017 | M | 2,707 | D | — | Dec 4, 2018 | Common Stock | 0 | 55,193 | D |
| Employee Stock Option (right to buy)F6 | $17.33 | May 3, 2017 | M | 2,293 | D | — | Dec 4, 2018 | Common Stock | 0 | 52,900 | D |
Explanation of responses
- F1Includes an aggregate of 45,294 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
- F2These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on June 6, 2016.
- F3Represents weighted average sale price. Actual sale prices ranged from $30.77 to $31.76.
- F4Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
- F5Represents weighted average sale price. Actual sale prices ranged from $31.84 to $32.13.
- F6The option became exercisable as to 25% of the shares on December 4, 2009, and became exercisable as to 1/48th of the shares each full month thereafter.